keyword
https://read.qxmd.com/read/38133595/in-brief-three-new-injectable-antipsychotic-drugs
#1
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
December 25, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/37693824/fabrication-optimization-and-characterization-of-an-osmotic-push-pull-drug-delivery-system-for-paliperidone
#2
JOURNAL ARTICLE
Sayali A Nangare, Asif H Ali, Kakasaheb R Mahadik, Sharvil S Patil
OBJECTIVES: Paliperidone is a BCS class II drug with low solubility and high permeability. It has 28% absolute oral bioavailability and an elimination half-life of 23 h. An osmotic push-pull trilayer tablet currently available on the market has achieved controlled release of a low dose over an extended time period, while avoiding the need for a loading dose. However, this trilayer tablet has several disadvantages, such as complicated processing, high production costs and difficulty in achieving uniformity of the contents...
December 2023: Journal of Taibah University Medical Sciences
https://read.qxmd.com/read/37632081/cheminformatics-strategies-unlock-marburg-virus-vp35-inhibitors-from-natural-compound-library
#3
JOURNAL ARTICLE
Isra M Alsaady, Leena H Bajrai, Thamir A Alandijany, Hattan S Gattan, Mai M El-Daly, Sarah A Altwaim, Rahaf T Alqawas, Vivek Dhar Dwivedi, Esam I Azhar
The Ebola virus and its close relative, the Marburg virus, both belong to the family Filoviridae and are highly hazardous and contagious viruses. With a mortality rate ranging from 23% to 90%, depending on the specific outbreak, the development of effective antiviral interventions is crucial for reducing fatalities and mitigating the impact of Marburg virus outbreaks. In this investigation, a virtual screening approach was employed to evaluate 2042 natural compounds for their potential interactions with the VP35 protein of the Marburg virus...
August 15, 2023: Viruses
https://read.qxmd.com/read/37051282/invega-hafyera-paliperidone-palmitate-extended-release-injectable-suspension-for-patients-with-schizophrenia
#4
REVIEW
Lindsey Peters, Megan Dyer, Emily Schroeder, Manoranjan S D'Souza
Objective: The objective of this study was to describe the safety, efficacy, and potential role in therapy of once in 6 months paliperidone palmitate formulation (PP6M; Invega Hafyera). PP6M is a long-acting injectable antipsychotic recently approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia. Data Sources: A PubMed literature search was conducted using the following terms: paliperidone palmitate and long-acting antipsychotic injections (January 1, 2017, to November 1, 2022)...
April 2023: Journal of Pharmacy Technology: JPT: Official Publication of the Association of Pharmacy Technicians
https://read.qxmd.com/read/36839950/leveraging-physiologically-based-modelling-to-provide-insights-on-the-absorption-of-paliperidone-extended-release-formulation-under-fed-and-fasting-conditions
#5
JOURNAL ARTICLE
Saima Subhani, Viera Lukacova, Chaejin Kim, Leyanis Rodriguez-Vera, Paula Muniz, Monica Rodriguez, Rodrigo Cristofoletti, Sandra Van Os, Elena Suarez, Stephan Schmidt, Valvanera Vozmediano
Paliperidone was approved by the US FDA in 2006 as an extended-release (ER) tablet (Invega® ) for the once-daily treatment of schizophrenia. This osmotic-controlled release oral delivery system (OROS) offers advantages, such as the prevention of plasma concentration fluctuation and reduced dosing frequency. The administration of the ER after a high-fat/high-calorie meal leads to increased maximum plasma concentration and area under the curve values by 60% and 54%, respectively. Food has various effects on gastrointestinal (GI) physiology, including changed transit times, changed volumes, altered pH in different GI compartments, secretion of bile salts, and increased hepatic blood flow...
February 13, 2023: Pharmaceutics
https://read.qxmd.com/read/36225523/acute-dystonia-with-rhabdomyolysis-induced-by-paliperidone-palmitate-a-rare-adverse-effect
#6
Nishant Allena, Sai Doppalapudi, Sneha Khanal, Steven Tank, Rabih Nasr
Antipsychotic medications have been well-established to potentially cause extrapyramidal side effects (EPS) including hyperkinesia, tremor, dyskinesia, dystonia, and parkinsonism. Rhabdomyolysis secondary to extrapyramidal symptoms in patients under antipsychotics is a relatively rare presentation to be observed in patients.  In this report, we present a 64-year-old female with rhabdomyolysis following a once-monthly injection of long-acting injectable (LAI) paliperidone palmitate (Invega Sustenna). The patient developed extrapyramidal symptoms one day after the paliperidone injection...
September 2022: Curēus
https://read.qxmd.com/read/36047719/microcrystals-of-ketal-linked-paliperidone-prodrugs-for-long-acting-antipsychotics
#7
JOURNAL ARTICLE
Zunkai Xu, Tao Liu, Yaoyao Jiang, Zhixia Chen, Xiaoguang Shi, Yang Xu, Na Yu, Xia Hua, Xing-Jie Liang, Xiaoyong Yuan, Shutao Guo
Intramuscularly injectable long-acting prodrug-based microcrystals (MCs) are of particular interest for chronic disease management. Nevertheless, current prevalently used linkers degraded by enzymes have the potential drawback of substantial differences in enzyme levels between individuals. Here, we reported the synthesis of a stearyl-modified paliperidone prodrug (SKP) with an acid-sensitive ketal linker for developing long-acting MC antipsychotics. SKP-MCs of three different sizes were prepared and systematically examined...
September 1, 2022: Molecular Pharmaceutics
https://read.qxmd.com/read/35730516/letter-to-the-editor-rethinking-the-cost-of-antipsychotic-treatment-the-average-cost-of-the-drugs-used-in-turkey-in-2020
#8
JOURNAL ARTICLE
Mustafa Yıldız, Emre Osman
Dear Editor, The costs of antipsychotic drugs (APDs) used in the treatment of mental disorders with psychosis are mentioned in treatment guidelines (APA 2021, NICE 2014). While the American Psychiatric Association guideline states that every specialist should make decisions according to the rules and conditions of their country and their region, the National Institute of Health and Clinical Excellence guideline emphasizes that drug costs must be taken into consideration in the treatment process. Classical or first-generation antipsychotic drugs (FAPDs) are relatively cheaper in terms of sales prices compared to atypical or second-generation antipsychotic drugs (SAPDs) with a slightly different effect mechanism...
2022: Türk Psikiyatri Dergisi, Turkish Journal of Psychiatry
https://read.qxmd.com/read/35631680/comparison-of-paliperidone-palmitate-from-different-crystallization-processes-and-effect-on-formulations-in-vitro-and-in-vivo
#9
JOURNAL ARTICLE
Junfeng Shi, Dan Wang, Yang Tian, Zengming Wang, Jing Gao, Nan Liu, Xiang Gao, Aiping Zheng, Hui Zhang, Meixian Xiang
The quality of active pharmaceutical ingredients (APIs) is an important factor which can affect the safety and efficacy of pharmaceuticals. This study was designed to investigate the nature of paliperidone palmitate (PP) obtained by different crystallization processes, then compare the characteristics between test formulations which prepared PP of different crystallization and reference formulations (Invega Sustenna® ) in vitro and in vivo. Two different PPs, namely PP-1 and PP-2, were prepared by different crystallization methods...
May 20, 2022: Pharmaceutics
https://read.qxmd.com/read/34621193/paliperidone-3-month-injection-for-treatment-of-schizophrenia-a-narrative-review
#10
REVIEW
Amber N Edinoff, Prithvi K Doppalapudi, Claudia Orellana, Caroline Ochoa, Shelby Patti, Yahya Ghaffar, Elyse M Cornett, Aaron J Kaye, Omar Viswanath, Ivan Urits, Adam M Kaye, Alan D Kaye
Given the typical age onset of schizophrenia, there are tremendous economic and social impacts that extend beyond the person and their families. One critical determinant of the diseases' impact is the patient's adherence to antipsychotic drug treatment. Approved in 2015 for the treatment of schizophrenia, paliperidone palmitate (Invega Trinza, a 3-month injection, noted as PP3M) is a second-generation long-acting injectable antipsychotic medication. Among the different formulations offered for palmitate paliperidone, including the 1 and 3-month formulations, the longer duration 3-month formulation was better at preventing relapse in schizophrenic patients...
2021: Frontiers in Psychiatry
https://read.qxmd.com/read/33230596/arrhythmias-related-to-antipsychotics-and-antidepressants-an-analysis-of-the-summaries-of-product-characteristics-of-original-products-approved-in-germany
#11
JOURNAL ARTICLE
Mohamed Elsayed, Emaad Abdel-Kahaar, Maximilian Gahr, Bernhard J Connemann, Michael Denkinger, Carlos Schönfeldt-Lecuona
PURPOSE: Most psychiatric drugs, such as antidepressants (AD) and antipsychotics (AP), may cause cardiac adverse events (CAE). We used summaries of product characteristics (SmPC) for assessing the likelihood of AD and AP to cause CAE. METHODS: We identified all original medicinal products (OMP) of AD and AP approved in Germany. We searched for their SmPCs using the online services of PharmaNet.Bund, Gelbe liste®, Rote Liste®, Fachinfo-Service®, and via manufacturer contact...
May 2021: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/31730504/need-for-bioequivalence-standards-that-reflect-the-clinical-importance-of-the-complex-pharmacokinetics-of-paliperidone-palmitate-long-acting-injectable-suspension
#12
JOURNAL ARTICLE
Ric M Procyshyn, Joel W Lamoure, Martin A Katzman, Pamela L Skinner, Stephen E Sherman
Paliperidone palmitate is a second generation antipsychotic, approved for the treatment of schizophrenia in the form of the long-acting injectable (LAI) products INVEGA SUSTENNA® (once monthly injection) and INVEGA TRINZA® (once every 3 months injection). Paliperidone palmitate dissolves slowly after deep intramuscular injection before being hydrolyzed to paliperidone and absorbed into the systemic circulation. The pharmacokinetic (PK) profile of the INVEGA SUSTENNA® formulation is biphasic, comprised of an initial relatively fast zero-order input, which allows rapid attainment of therapeutic concentrations without oral supplementation; and a subsequent maintained second-stage, first-order input, allowing for once monthly administration...
2019: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/28044455/health-care-resource-utilization-and-costs-of-california-medicaid-patients-with-schizophrenia-treated-with-paliperidone-palmitate-once-monthly-or-atypical-oral-antipsychotic-treatment
#13
JOURNAL ARTICLE
Jacqueline A Pesa, Dilesh Doshi, Li Wang, Huseyin Yuce, Onur Baser
OBJECTIVE: To compare all-cause health care utilization and costs between patients with schizophrenia treated with once monthly paliperidone palmitate (PP1M; Invega Sustenna 1 ) and atypical oral antipsychotic therapy (OAT). METHODS: This was a retrospective claims-based analysis among adult California Medicaid (Medi-Cal) patients with schizophrenia having ≥2 claims for PP1M or OAT from 1 July 2009 to 31 December 2013 and continuous health plan enrollment for ≥1 year pre- and post-index date (PP1M or OAT initiation date)...
April 2017: Current Medical Research and Opinion
https://read.qxmd.com/read/27699643/paliperidone-palmitate-intramuscular-3-monthly-formulation-a-review-in-schizophrenia
#14
JOURNAL ARTICLE
Yvette N Lamb, Gillian M Keating
A 3-monthly formulation of intramuscular paliperidone palmitate (3-monthly paliperidone palmitate) has recently been approved for the maintenance treatment of schizophrenia in adult patients in the EU (Trevicta® ), following earlier approval in the USA (Invega Trinza® ). This narrative review discusses the clinical use of 3-monthly paliperidone palmitate in the maintenance treatment of schizophrenia in adult patients and summarizes its pharmacological properties. The efficacy of the 3-monthly paliperidone palmitate formulation as a maintenance treatment for schizophrenia has been demonstrated in well designed, phase III trials...
October 2016: Drugs
https://read.qxmd.com/read/27069340/invega-trinza-the-first-four-times-a-year-long-acting-injectable-antipsychotic-agent
#15
JOURNAL ARTICLE
Noor Daghistani, Jose A Rey
Paliperidone palmitate three-month injection (Invega Trinza): the first four-times-a-year, long-acting injectable antipsychotic agent for schizophrenia.
April 2016: P & T: a Peer-reviewed Journal for Formulary Management
https://read.qxmd.com/read/25043337/population-pharmacokinetic-modeling-and-simulation-to-guide-dose-selection-for-rbp-7000-a-new-sustained-release-formulation-of-risperidone
#16
RANDOMIZED CONTROLLED TRIAL
Celine M Laffont, Roberto Gomeni, Bo Zheng, Christian Heidbreder, Paul J Fudala, Azmi F Nasser
RBP-7000 is a long-acting formulation of risperidone designed for once-monthly subcutaneous injection for the treatment of schizophrenia. The objective was to estimate clinically effective doses of RBP-7000 based on model simulations and on the comparison with other long-acting injectable antipsychotics. A population pharmacokinetic model of RBP-7000 was developed in 90 clinically stable schizophrenic patients having received single/repeated doses of 60, 90, or 120 mg. Model simulations were conducted to compare active moiety plasma exposure after repeated RBP-7000 administrations to the published data of long-acting risperidone injection (Risperdal® Consta®) at 25 and 50 mg, and of paliperidone palmitate (Invega® Sustenna®) at 50 and 100 mg equivalent paliperidone...
January 2015: Journal of Clinical Pharmacology
https://read.qxmd.com/read/23422374/an-integrated-approach-for-establishing-dosing-recommendations-paliperidone-for-the-treatment-of-adolescent-schizophrenia
#17
RANDOMIZED CONTROLLED TRIAL
Islam Rasem Younis, Thomas P Laughren, Yaning Wang, Mitchell Mathis, Jogarao V Gobburu
The Food and Drug Administration recently approved Invega for the treatment of schizophrenia in adolescents 12 to 17 years. If dosing recommendations for this population would have been based only on the results of the single efficacy trial included in this program, paliperidone dosing in adolescents might have been limited to 3 mg/d in adolescents less than 51 kg and to 6 mg/d in adolescents greater than or equal to 51 kg. This article provides an illustration of a more integrated approach to arrive at dosing recommendation that included practical considerations, modeling and simulation of data from the clinical trial, and the totality of evidence for both paliperidone and the parent drug, risperidone...
April 2013: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/23257415/-evaluation-of-dissolution-of-osmotic-controlled-release-paliperidone-tablets-using-the-reciprocating-cylinder-method
#18
JOURNAL ARTICLE
Shunji Nagata, Aya Jin-nai, Ken-ichi Hirai, Mikako Baba, Kousuke Higashi, Yusuke Tanaka
The dissolution profiles of paliperidone from INVEGA(®) 3-mg tablets, osmotic-controlled release tablets, were evaluated by using the reciprocating cylinder method (RC method). We used 4 different compositions of the dissolution fluids, by considering the environment of the tablet in the gastrointestinal tract. After a lag time of 2 to 4 h, paliperidone was approximately dissolved to 24 h by zero-order release. The dissolution characteristics of paliperidone were not affected by the kind of the test medium, pH, and surfactant...
2013: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://read.qxmd.com/read/23237347/the-pharmacology-and-formulation-of-paliperidone-extended-release
#19
REVIEW
Pierre S Chue, Erin M MacKenzie, James A Chue, Glen B Baker
Paliperidone, or 9-hydroxyrisperidone (Invega(®), Janssen, Antwerp, Belgium) is the major active metabolite of the atypical antipsychotic risperidone (Risperdal(®), Janssen). It possesses a similar, though not identical, receptor pharmacology to the parent molecule. There are additional differences in terms of its predominant renal metabolism, lower protein binding and decreased inhibition of P-glycoprotein leading to decreased potential for drug-drug interactions. Paliperidone is approved as an extended release (ER) tablet based on an osmotic-controlled release oral Push-Pull™ delivery system (Oral Osmotic System, OROS(®), Alza Corporation) for the treatment of schizophrenia...
December 2012: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/23237346/a-review-of-paliperidone-palmitate
#20
REVIEW
Pierre Chue, James Chue
Risperidone long-acting injection (RLAI) was the first second-generation antipsychotic available as a long-acting injection. Paliperidone (9-hydroxyrisperidone) is the active metabolite of risperidone, introduced initially as an extended release oral (ORal Osmotic System, OROS®, Alza Corporation) formulation (Invega®, Janssen). Paliperidone long-acting injection (PLAI) has now been developed as a suspension of paliperidone palmitate nanocrystals in an aqueous formulation (Invega Sustenna®, Xeplion®), administered monthly by intramuscular injection (deltoid or gluteal)...
December 2012: Expert Review of Neurotherapeutics
keyword
keyword
70684
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.